A biopharmaceutical company that is seeking FDA approval for a drug to treat infantile spasms plans to open a new office in Columbia.
Questcor Pharmaceuticals Inc. has signed a lease for a 6,186-square-foot office at Columbia Corporate Park. The new office is located at 6011 University Blvd. and will open Nov. 1.
Based in Union City, Calif., Questcor primarily focuses on treating rare central nervous system disorders. It is currently seeking FDA approval for its H.P. Acthar Gel to treat infantile spasms. The decision was supposed to come last month, but was delayed by the FDA. The drug is currently used to treat multiple sclerosis.
The Columbia office will focus on clinical research and regulatory affairs.
"Due to the significant growth Questcor has experienced and expects to continue, we are significantly expanding our R&D workforce in Columbia," said Dr. David Young, chief scientific officer, in a statement.
The company will be adding several employees to the office, including a vice president of clinical research, a manager of regulator affairs and a director of clinical research.
Questcor signed the lease with Baltimore's Merritt Properties LLC. Other leases Merritt has signed this year at Columbia Corporate Park include White Cliffs Consulting LLC, Trusant Technologies LLC and
Maroon PR.
Questcor's drug Doral is used to treat insomnia.
Writer: Julekha Dash
Source: Dr. David Young, Questcor